骨质疏松症对接受前列腺癌治疗的男性的影响。
The impact of osteoporosis in men treated for prostate cancer.
作者信息
Oefelein Michael G, Resnick Martin I
机构信息
Department of Urology, Case Western Reserve University School of Medicine, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, OH 44106, USA.
出版信息
Urol Clin North Am. 2004 May;31(2):313-9. doi: 10.1016/j.ucl.2004.02.002.
Prostate cancer patients are at significant risk for SREs, with up to 50% of androgen-insensitive patients experiencing an SRE at 24 months. The risk increases with the duration and type of cancer treatment. SREs decrease HRQOL, increase the cost of care, and are associated negatively with overall survival. Screening men at greatest risk (slender white men and men with hormone refractory disease or metastatic disease) with BMD measurements, and initiating empiric therapy (vitamin D3, calcium, parenteral estrogens, bisphosphates) may be warranted.
前列腺癌患者发生骨相关事件（SREs）的风险很高，高达50%的雄激素不敏感患者在24个月时会发生一次SREs。风险会随着癌症治疗的持续时间和类型而增加。SREs会降低健康相关生活质量（HRQOL），增加护理成本，并与总生存期呈负相关。对风险最高的男性（身材消瘦的白人男性以及患有激素难治性疾病或转移性疾病的男性）进行骨密度测量筛查，并启动经验性治疗（维生素D3、钙、胃肠外雌激素、双膦酸盐）可能是必要的。
Zotero 插件